Single-institution results of primary external-beam radiation for the treatment of T1-T3 prostate cancer

Strahlentherapie und Onkologie

Volumn 183, Issue 6, 2007, Pages 321-326

  Weiss, Wolfgang ^a   Horninger, Wolfgang ^a   Forthuber, Britta C ^a   Ulmer, Hanno ^a   Lukas, Peter ^a   Sweeney, Reinhart A ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Prostate cancer; Radiotherapy; Survival; Toxicity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BEAM THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; GLEASON SCORE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROSTATE CANCER; RADIATION INJURY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACTUARIAL ANALYSIS; AGED; CAUSE OF DEATH; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 34347258086     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-007-1672-7     Document Type: Article

References (19)

1. Amt der Tiroler Landesregierung. Demographische Daten für Tirol 2003. Innsbruck: Amt der Tiroler Landesregierung, 2003.
2. Beckendorf V, Guerif S, Le PE, et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 2004;60:1056-65.
3. Cavey ML, Bayouth JE, Colman M, et al. IMRT to escalate the dose to the prostate while treating the pelvic nodes. Strahlenther Onkol 2005;181:431-41.
4. Geinitz H, Zimmermann F, von Wedel E, et al. [Biochemical control after conformal, 3 dimensional radiotherapy of prostatic carcinoma.] Strahlenther Onkol 2002;178:369-77.
5. Gerstner N, Wachter S, Dorner D, et al. [Significance of a rectal balloon as internal immobilization device in conformal radiotherapy of prostatic carcinoma.] Strahlenther Onkol 1999;175:232-8.
6. Goldner G, Wachter S, Wachter-Gerstner N, et al. Long-term results in three-dimensional conformal radiotherapy of localized prostate cancer at moderate dose (66 Gy). Strahlenther Onkol 2006;182:537-42.
7. Hille A, Schmidberger H, Tows N, et al. The impact of varying volumes in rectal balloons on rectal dose sparing in conformal radiation therapy of prostate cancer. A prospective three-dimensional analysis. Strahlenther Onkol 2005;181:709-16.
8. Kestin LL, Vicini FA, Martinez AA. Practical application of biochemical failure definitions: what to do and when to do it. Int J Radiat Oncol Biol Phys 2002;53:304-15.
9. Koswig S, Dinges S, Buchali A, et al. [Comparison of different 3-dimensional irradiation techniques in local radiotherapy of prostatic carcinoma.] Strahlenther Onkol 1999;175:10-6.
10. Kupelian PA, Mohan DS, Lyons J, et al. Higher than standard radiation doses (> or = 72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2000;46:567-74.
11. Kwan W, Pickles T, Duncan G, et al. PSA failure and the risk of death in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:1040-6.
12. Mayer R, Pummer K, Quehenberger F, et al. Analysis of competing risk parameters in irradiated prostate cancer patients. Strahlenther Onkol 2003;179:452-7.
13. Mock U, Bogner J, Georg D, et al. Comparative treatment planning on localized prostate carcinoma. Conformal photon- versus proton-based radiotherapy. Strahlenther Onkol 2005;181:448-55.
14. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005;61:1019-34.
15. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 2003;57:929-43.
16. Valicenti R, Lu J, Pilepich M, et al. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol 2000;18:2740-6.
17. Wachter S, Gerstner N, Dieckmann K, et al. [Planned 3-dimensional low-volume conformal irradiation of a local prostatic carcinoma.] Strahlenther Onkol 1997;173:253-60.
18. Wagner W, Ostkamp K, Niewohner-Desbordes U. [A simple method for transposing MRI information to simulation films. Technical note.] Strahlenther Onkol 2000;176:235-8.
19. Williams SG, Duchesne GM, Millar JL, et al. Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004;60:1082-7.